Xydalba covers the most common Gram-positive pathogens in ABSSSI5

  • Methicillin resistance has no impact on Xydalba activity1
  • Efficacy has been demonstrated in clinical studies against the pathogens listed for ABSSSI that were susceptible to Xydalba in vitro1:
    • Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA)
    • Streptococcus pyogenes
    • Streptococcus agalactiae
    • Streptococcus dysgalactiae
    • Streptococcus anginosus group (includes S. anginosus, S. intermedius, and S. constellatus)
  • MIC90 for S. aureus and S. pyogenes is 0.06 µg/ml2

Antibacterial activity against other relevant pathogens1

  • Clinical efficacy has not been established against the following pathogens although in vitro studies suggest that they would be susceptible to Xydalba in the absence of acquired mechanisms of resistance:
    • Group G streptococci
    • Clostridium perfringens
    • Peptostreptococcus spp
MIC90= minimum inhibitory concentration required to inhibit the growth of 90% of bacterial isolates
1 Xydalba SmPC
5 FDA. Guidance for Industry. Acute Bacterial Skin and Skin Structure Infections: Developing Drugs for Treatment. October 2013. https://www.fda.gov/downloads/Drugs/Guidances/ucm071185.pdf; Accessed June 28, 2017